EVERSANA

WIPO WIPO 2019

Schützen Sie diese Marke vor Nachahmern!

Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.

Die Internationale Marke EVERSANA wurde als Wortmarke am 16.01.2019 bei der Weltorganisation für geistiges Eigentum angemeldet.

Markendetails Letztes Update: 22. März 2023

Markenform Wortmarke
Aktenzeichen 1495984
Länder Australien Schweiz China Europäische Gemeinschaft Indien Japan Südkorea Singapur
Basismarke US Nr. 88054633, 26. Juli 2018
Anmeldedatum 16. Januar 2019
Ablaufdatum 16. Januar 2029

Markeninhaber

190 N Milwaukee St
Milwaukee WI 53202
US

Markenvertreter

Saul Ewing LLP, 33 South Sixth Street, Suite 4750 US

Waren und Dienstleistungen

35 Business consultation services in the health care and biopharma industry; market research services, for drug companies, biologic companies, medical device companies, or other companies in the healthcare field; clinical trial referral services, namely, posting of clinical trial notices for the purpose of recruiting patients for participation in clinical trials for the testing of drugs; call-center support services, namely, operation of telephone call centers for others; business services provided to the life sciences, biopharmaceutical, and medical technology industries, namely, reporting and collecting biopharmaceutical and medical technology product complaints; business consulting services in the life sciences field; business management services in the healthcare field; import and export agency services; providing advertising, marketing and promotional services for the pharmaceutical and medical industry; operation of telephone call centers for others in the field of pharmaceutical, biotechnology, medical devices and healthcare manufactures; providing information as to the availability of pharmaceutical, biotechnology, medical devices, healthcare and life sciences goods and services for purchase via an online database; patient relationship management services; advertising, promotion, and marketing services for the pharmaceutical, biotech and medical industries; pharmaceutical services, namely, processing online and telephone prescription orders in specialty pharmacies; pharmaceutical cost management services and drug utilization review services; mail order pharmacy services; business consulting services in the life sciences field; business management services in the life sciences field; providing trade information in the field of pharmaceutical, biotechnology and healthcare manufacturer product pricing, reimbursement data and assistance, and management of copays, via an on-line computer database; providing business intelligence in the fields of medical devices, pharmaceuticals and life sciences, via an online database; patient assistance program support services, namely, customer service management for others; retail and specialty retail pharmacy services; maintaining patient medical records and files
36 Financial services, namely, financial analysis and payer reimbursement, namely, reimbursement payment processing in the field of biopharmaceutical and medical technology products claims; providing insurance information about patient healthcare benefit verification services, patient reimbursement and insurance coverage for pharmaceuticals and medical devices, via a website; medical insurance case and utilization review and insurance claims adjustment services for healthcare purchasers and payors; online information services, namely, providing information on insurance formulary coverage changes provided by healthcare companies to external stakeholders such as healthcare providers and patients, and receiving input about insurance plan formulary coverage or policy changes from a user via an online portal and populating pre-existing templates of materials for external audiences; providing insurance information and statistics about patient reimbursement and insurance coverage for pharmaceuticals and medical devices, via an online computer database; financial administration of patient reimbursement programs; financial administration of pharmacy reimbursement programs and services; insurance management services relating to pharmaceuticals
38 Communications services, namely, transmission of voice, audio, visual images and data by telecommunications networks, wireless communication networks, the Internet, information services networks and data networks in the field of managed healthcare markets; electronic data interchange services in the field of healthcare transactions such as claims, eligibility, claim status, electronic remittance advice, prior authorizations, attachments and referrals that allow direct transaction and payment communications between healthcare providers and payers
39 Supply chain services, namely, warehousing and transportation and delivery of goods for others by air, rail, ship, truck; pharmacy packaging services; reverse logistics packaging services
42 Research and testing services in the field of pharmaceutical, biotechnology, medical devices and healthcare; medical research; conducting clinical trials for others in the life sciences, biopharmaceutical, and medical technology fields; hosting a website featuring technology to allow users to determine a patient's healthcare benefit verification services, a patient's prescription medication co-payment, to process insurance company approvals and to verify prescription medication; computer software consultancy rendered to pharmaceutical companies in the field of drug pricing and medical device pricing; providing a web hosting platform for hosting virtual advisory boards, speaker trainings and peer-to-peer programs for stakeholders in the health care community, namely, medical and pharmaceutical suppliers, healthcare professionals and payer representatives
44 Consulting services in the field of healthcare for pharmaceutical, biotechnology and healthcare manufactures; health care services, namely, managed health care services; pharmaceutical advice; dispensing pharmaceuticals; providing information to patients in the field of administering medications; provision of healthcare information in the field of physician groups services, health systems and hospitals, HMOs [Health Maintenance Organizations] and insurance providers, regional market data, drug product and customer response data; patient support services and patient advocacy services, namely, providing health care information by telephone; patient support services, namely, medical consultations provided via phone, online chat or videoconferencing; patient support services and patient advocacy services, namely, consulting services in the field of health; providing health care management services for coordinating medical, physical, social, personal care and psychological assistance in the field of health care, acute and chronic disease management, long-term care, cancer treatment, and medical treatment; providing health care management services for coordinating the procurement and administration of medication (terms considered too vague by the International Bureau - Rule 13(2)(b) of the Common Regulations)
45 Providing licensing, regulatory, and compliance services, namely, licensing of intellectual property, regulatory compliance consulting in the life sciences, biopharmaceutical, and medical technology fields, reviewing standards and practices to assure compliance with food and drug industry laws and regulations; providing patient advocate services to hospital patients and patients in long term care facilities; providing patient advocate services to individuals in need of medical and health care services
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen

Markenhistorie

Datum Belegnummer Bereich Eintrag
02. Dezember 2021 2021/49 Gaz JP RAW: Rule 18ter(2)(ii) GP following a provisional refusal
09. Juni 2021 2021/23 Gaz KR RAW: Rule 18ter(2)(ii) GP following a provisional refusal
04. Februar 2021 2021/5 Gaz JP Ablehnung
06. Januar 2021 2021/4 Gaz CH RAW: Rule 18ter(2)(ii) GP following a provisional refusal
01. Oktober 2020 2020/41 Gaz CH Ablehnung
30. September 2020 2020/45 Gaz US RAW: Partial Ceasing Effect
13. September 2020 2020/43 Gaz SG RAW: Rule 18ter(2)(ii) GP following a provisional refusal
24. August 2020 2020/35 Gaz IN Ablehnung
19. August 2020 2020/34 Gaz KR Ablehnung
12. Juni 2020 2020/29 Gaz EM RAW: Rule 18ter(2)(ii) GP following a provisional refusal
22. April 2020 2020/17 Gaz AU Ablehnung
22. Januar 2020 2020/5 Gaz CN Ablehnung
29. November 2019 2019/49 Gaz SG Ablehnung
08. November 2019 2019/47 Gaz EM Ablehnung
16. Januar 2019 2019/42 Gaz US Eintragung

ID: 141495984